Nancy Hampton-Jones
Clinical Nurse Specialist · Dayton, OHNPI 1881001535
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,936 of the $4,602 with a category attached, or 85.5%. It is spread thinly across 36 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Among clinical nurse specialist clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $43.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$569
- Gilead$399
- Johnson & Johnson$367
- Sanofi$344
- AstraZeneca$251
- G1 Therapeutics, Inc.$243
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,93686%
- Education$66614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $569 |
| Gilead | 6 | $399 |
| Johnson & Johnson(2 entities) | 6 | $367 |
| Sanofi | 5 | $344 |
| AstraZeneca(2 entities) | 5 | $251 |
| G1 Therapeutics, Inc. | 7 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $235 |
| AbbVie | 7 | $233 |
| Amgen | 11 | $206 |
| Daiichi Sankyo Inc. | 2 | $159 |
| Rigel Pharmaceuticals, Inc. | 2 | $142 |
| Seagen Inc. | 3 | $130 |
| Astellas Pharma US Inc | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 2 | $111 |
| Genentech USA, Inc. | 2 | $103 |
| Incyte Corporation | 2 | $96 |
| Sobi, Inc | 1 | $94 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Genmab U.S., Inc. | 1 | $84 |
| Novartis | 4 | $79 |
| Pfizer | 1 | $77 |
| Merck | 3 | $61 |
| Blueprint Medicines Corporation | 3 | $56 |
| Integra Lifesciences Corporation | 1 | $54 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $37 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| Novocure Inc. | 1 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Myriad Genetic Laboratories, Inc. | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Array Biopharma Inc | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Biogen | 1 | $19 |
| GSK | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,602 in reported general payments places this provider in the 90th percentile of 97 clinical nurse specialist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 25 | $440,709 |
| IbrancePalbociclib | 25 | $394,765 |
| Lenalidomide | 28 | $369,038 |
| BrukinsaZanubrutinib | 23 | $329,465 |
| InlytaAxitinib | 12 | $244,347 |
| TagrissoOsimertinib Mesylate | 11 | $184,174 |
| Abiraterone Acetate | 12 | $35,061 |
| EliquisApixaban | 45 | $32,999 |
| XareltoRivaroxaban | 14 | $8,545 |
| Exemestane | 44 | $8,011 |
| Fentanyl | 54 | $5,285 |
| Ondansetron Hcl | 20 | $3,098 |
| Oxycodone Hcl | 47 | $2,587 |
| Anastrozole | 135 | $1,932 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 39 | $1,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Inlyta, Eliquis | $77 | $672,11182 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $37 | $440,70925 claims |
| AstraZenecaTagrisso | $251 | $184,17411 claims |
| Johnson & JohnsonXarelto | $367 | $8,54514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 97 clinical nurse specialist providers in Ohio.
Other clinical nurse specialist in Dayton
- Cynthia SchwartzDayton$835
- Marjorie DerksenDayton$396
- Deborah HurstDayton$193
- Michelle PostDayton$151
- Nancy AlbertChesterland$114K
- Frank GargaszBoardman$37K
- Jennifer WoodsAkron$19K
- Nancy BairCleveland$13K
- Maria HeldCleveland$7K
- Rebecca ThomasAkron$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.